Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Plasma biomarkers in neuropsychiatric syndromes: A narrative review.
Journal: Journal of Alzheimer's disease : JAD
Published: November 24, 2025
Ketogenic drug tricaprilin (CER-0001) for the treatment of refractory infantile epileptic spasms: a phase 1/2a study.
Journal: Frontiers in pediatrics
Published: February 11, 2025
Response to Aanwat et al. on chow et al. Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study JONS July 22, 2024.
Journal: Journal of the neurological sciences
Published: September 08, 2024
Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study.
Journal: Journal of the neurological sciences
Published: May 27, 2024
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.
Journal: The journal of prevention of Alzheimer's disease
Published: January 17, 2024
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.
Journal: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Published: May 07, 2021
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Journal: Alzheimer's research & therapy
Published: November 12, 2020
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Journal: Journal of Parkinson's disease
Published: August 18, 2020
Mechanisms underlying resilience in ageing.
Journal: Nature reviews. Neuroscience
Published: March 01, 2019
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria - CORRIGENDUM.
Journal: International psychogeriatrics
Published: November 22, 2018
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
Journal: European journal of drug metabolism and pharmacokinetics
Published: April 06, 2018
Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
Journal: Clinical and translational science
Published: November 13, 2017
Last Updated: 09/26/2026